Literature DB >> 2153737

Antiviral antibody responses in mothers and their newborn infants with clinical and subclinical congenital cytomegalovirus infections.

W J Britt1, L G Vugler.   

Abstract

Human cytomegalovirus (HCMV)-specific antibodies were assayed in cord serum and the respective maternal serum from two groups of newborn infants with congenital HCMV infection. One group of infants exhibited clinically apparent infection with multiple organ system involvement, whereas the second group had subclinical infections. Levels of virus-specific IgG antibodies reactive with several virus-encoded proteins including those reactive with the major envelope glycoprotein complex were significantly higher in cord serum and maternal delivery serum from the group of infants with clinically apparent infection than in serum from those with subclinical infection. Maternal delivery serum from the group with subclinical infection had significantly higher levels of IgM virus-binding antibody and lower levels of IgG virus-binding antibody than did the respective serum from the group with clinically apparent infection, suggesting maternal acquisition occurred later in gestation in the group with subclinical infection. These results suggested that deficiencies in the HCMV-specific antibody response were not associated with clinically apparent congenital infection and that other factors, such as early virus acquisition during pregnancy, might contribute to the severity of intrauterine HCMV infection.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2153737     DOI: 10.1093/infdis/161.2.214

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

1.  An acidic cluster in the cytosolic domain of human cytomegalovirus glycoprotein B is a signal for endocytosis from the plasma membrane.

Authors:  S Tugizov; E Maidji; J Xiao; L Pereira
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

Review 2.  Role of antibodies in confining cytomegalovirus after reactivation from latency: three decades' résumé.

Authors:  Astrid Krmpotić; Jürgen Podlech; Matthias J Reddehase; William J Britt; Stipan Jonjić
Journal:  Med Microbiol Immunol       Date:  2019-03-28       Impact factor: 3.402

3.  Cytomegalovirus induces interferon-stimulated gene expression and is attenuated by interferon in the developing brain.

Authors:  Anthony N van den Pol; Michael D Robek; Prabhat K Ghosh; Koray Ozduman; Prasanthi Bandi; Matthew D Whim; Guido Wollmann
Journal:  J Virol       Date:  2006-10-25       Impact factor: 5.103

4.  Permissive cytomegalovirus infection of primary villous term and first trimester trophoblasts.

Authors:  D G Hemmings; R Kilani; C Nykiforuk; J Preiksaitis; L J Guilbert
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

5.  Mutations in the carboxyl-terminal hydrophobic sequence of human cytomegalovirus glycoprotein B alter transport and protein chaperone binding.

Authors:  Z Zheng; E Maidji; S Tugizov; L Pereira
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

6.  Anti-viral effects of urosolic acid on guinea pig cytomegalovirus in vitro.

Authors:  Jingjing Zhao; Juanjuan Chen; Tao Liu; Jianguo Fang; Jin Wan; Jianhua Zhao; Wei Li; Jing Liu; Xianzhe Zhao; Suhua Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-12-28

7.  Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus.

Authors:  N Kniess; M Mach; J Fay; W J Britt
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

8.  Enhanced cytomegalovirus infection of developing brain independent of the adaptive immune system.

Authors:  Anthony N van den Pol; Jon D Reuter; Justin G Santarelli
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

9.  Site-specific glycosylation of the human cytomegalovirus tegument basic phosphoprotein (UL32) at serine 921 and serine 952.

Authors:  K D Greis; W Gibson; G W Hart
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

10.  A conditionally replication-defective cytomegalovirus vaccine elicits potent and diverse functional monoclonal antibodies in a phase I clinical trial.

Authors:  Leike Li; Daniel C Freed; Yaping Liu; Fengsheng Li; Diane F Barrett; Wei Xiong; Xiaohua Ye; Stuart P Adler; Richard E Rupp; Dai Wang; Ningyan Zhang; Tong-Ming Fu; Zhiqiang An
Journal:  NPJ Vaccines       Date:  2021-06-02       Impact factor: 7.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.